11669915001
Roche
Cell Proliferation ELISA, BrdU (chemiluminescent)
Synonyme(s) :
BrdU, cell proliferation
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Produits recommandés
Utilisation
sufficient for ≤1,000 tests
Niveau de qualité
Fabricant/nom de marque
Roche
Technique(s)
ELISA: suitable
Méthode de détection
chemiluminescent
Conditions d'expédition
wet ice
Température de stockage
2-8°C
Catégories apparentées
Description générale
Chemiluminescent immunoassay for the quantification of cell proliferation, based on the measurement of BrdU incorporation during DNA synthesis: a nonradioactive alternative to the [3H]-thymidine incorporation assay.
Spécificité
The antibody conjugate reacts with the thymidine analogue 5-bromo-2′-deoxyuridine (BrdU) and with BrdU incorporated into DNA. For binding to BrdU incorporated into the DNA, the BrdU-labeled DNA has to be denatured. The antibody does not cross-react with any endogenous cellular components such as thymidine, uridine, or DNA.
Application
Cell Proliferation ELISA, BrdU (chemiluminescent) has been used:
- for bromodeoxyuridine (BrdU) proliferation assay in ReN and primary astrocytes
- to test the effect on imatinib on the proliferation of neuroblastoma cells using BrdU incorporation assay
- to check the effect of palbociclib on cell cycle inhibition using BrdU incorporation in pancreatic patient-derived primary cell lines
The Cell Proliferation ELISA, BrdU (chemiluminescent) belongs to the second, improved generation of kits for measuring DNA synthesis. It is a precise, fast, and simple nonradioactive alternative to quantitate cell proliferation based on the measurement of BrdU incorporation during DNA synthesis in replicating (cycling) cells. Thus, the Cell Proliferation ELISA can be used in many different in vitro cell systems. For example:
- Detection and quantification of cell proliferation induced by growth factors and cytokines
- Determination of the inhibitory or stimulatory effects of various compounds on cell proliferation in environmental and biomedical research, and in the food, cosmetic, and pharmaceutical industries
- Measurement of the immunoreactivity of lymphocytes, stimulated by mitogens or antigens
- Analysis of the chemosensitivity of tumor cells to different cytostatic drugs in medical research
Conditionnement
1 kit containing 7 components.
Composants
- BrdU Labeling Reagent, 1,000x conc
- FixDenat
- Anti-BrdU-POD 4. Antibody Dilution Solution
- Washing Buffer PBS, 10x conc.
- Substrate Component A
- Substrate Component B
Autres remarques
For life science research only. Not for use in diagnostic procedures.
Composants de kit seuls
Réf. du produit
Description
- BrdU Labeling Reagent
- FixDenat ready-to-use
- Anti-BrdU-peroxidase antibody
- Antibody Dilution Solution ready-to-use
- ready-to-use 10x concentrated
- Substrate Component A
- Substrate Component B
Mention d'avertissement
Danger
Mentions de danger
Conseils de prudence
Classification des risques
Eye Irrit. 2 - Flam. Liq. 2 - Muta. 1B - Skin Sens. 1
Code de la classe de stockage
3 - Flammable liquids
Classe de danger pour l'eau (WGK)
WGK 1
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Les clients ont également consulté
Glycobiology, 25(8), 812-824 (2015-04-17)
The present study demonstrates that fucose-containing sulfated polysaccharides (FCSP) from brown algae interfere with the CXCL12/CXCR4 axis in human Burkitt's lymphoma cells by binding CXCL12 and thereby blocking both CXCL12-induced CXCR4 receptor activation and downstream effects like migration and secretion
Molecular medicine reports, 12(4), 5917-5923 (2015-08-25)
Epirubicin, an anthracycline derivative, is one of the main line treatments for brain tumors. The aim of the present study was to verify that epirubicin alters the growth and morphological characteristics of U‑87 glioma cells. In the present study, the
Oncotarget, 9(17), 13353-13365 (2018-03-24)
Nitric oxide (NO) exerts conflicting effect on tumor growth and progression, depending on its concentration. We aimed to characterize the anti-cancer activity of a new NO donor, Ni(SalPipNONO) belonging to the class of metal-nonoates, in epithelial derived tumor cells, finally
Cell, 161(3), 674-690 (2015-04-25)
Modulation of protein function is used to intervene in cellular processes but is often done indirectly by means of introducing DNA or mRNA encoding the effector protein. Thus far, direct intracellular delivery of proteins has remained challenging. We developed a
Oncotarget, 8(59), 100421-100432 (2017-12-17)
Esophageal adenocarcinoma (EAC) is a deadly disease with limited therapeutic options. In the present study, we determined the preclinical efficacy of CDK4/6 inhibitor abemaciclib for treatment of EAC. In vitro, apoptosis, proliferation, and pathway regulation were evaluated in OE19, OE33
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique